A similar review summarizes pharmacogenes associated with impaired TKI response in patients with CML, including cytochrome P450 3A4/5 (CYP3A4/5), human organic cation uptake transporter 1 (OCT1), ABCB1, and ABCG2, as well as the effect of epigenetics and microRNAs [44]. Here, ABCG2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.